Related Experiment Video
Updated: Jan 17, 2026
03:47
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
1.1K
Impact of Implementing a Pharmacy-Driven Intervention Bundle on Hospital Readmission Rates for Patients With Heart
Lara Tran1, Christine Rahme1, Sara Linnertz1
1St. Joseph's Health, Syracuse, NY, USA.
The Annals of Pharmacotherapy
|September 17, 2025
Summary
Pharmacy-driven heart failure interventions did not significantly reduce 30-day readmissions but increased guideline-directed medical therapy (GDMT) use. This highlights the potential of pharmacist-led care in improving heart failure management.
Area of Science:
- Cardiology
- Pharmacology
- Health Services Research
Background:
- Heart failure (HF) is a major cause of hospitalizations and readmissions.
- Pharmacy-driven interventions show promise in reducing HF readmissions and improving patient outcomes.
Purpose of the Study:
- To assess the impact of a pharmacy-driven intervention bundle on 30-day readmission rates in HF patients.
- To evaluate the effect of the intervention on guideline-directed medical therapy (GDMT) use and time to readmission.
Main Methods:
- Pre-post interventional study design with a control group receiving standard care and an intervention group receiving a heart failure-directed (HFD) pharmacy bundle.
- Primary outcome: 30-day readmission rate. Secondary outcomes: GDMT discharge rates and time to 30-day readmission.
Main Results:
- The HFD group had a 30-day readmission rate of 18.5% versus 21.2% in the control group (p=0.352).
- Significantly more patients in the HFD group were discharged on GDMT (34.9%) compared to the control group (8.5%) (P < 0.0001).
- The odds of readmission were nonsignificantly lower in the HFD group (OR 0.766).
Conclusions:
- Pharmacy-driven HFD interventions did not significantly decrease 30-day readmission rates for HF patients.
- The interventions led to a significant increase in the utilization of GDMT among discharged HF patients.
- Further research may explore optimizing these interventions to impact readmission rates more significantly.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.9K
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
532
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
261
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261
01:30Heart Failure VII: Nursing Interventions
422
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
422
01:30Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
01:22Heart Failure Drugs: β-Blockers
772
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
772
01:26Heart Failure Drugs: Inotropic Agents
1.3K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K